Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan

ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $238.98 per share on February 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 10, 2025, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
• The sale was executed at a price of $238.98 per share.
• The transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
• Following the transaction, Sandercock directly owns 91,864 shares of ResMed common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider transaction. It is neutral in sentiment as it simply reports facts.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This is a routine disclosure of a transaction by a company insider and doesn't necessarily reflect a broader industry trend. Insider sales are common and often pre-planned.

Stakeholder Impact

• The sale of shares by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

ResMed, Sandercock, CFO, Share Sale, Form 4, 10b5-1 Plan, RMD, Securities